• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

信号分子的协同作用使 CAR T 细胞的逻辑门控控制成为可能。

Co-opting signalling molecules enables logic-gated control of CAR T cells.

机构信息

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.

Department of Bioengineering, Stanford University, Stanford, CA, USA.

出版信息

Nature. 2023 Mar;615(7952):507-516. doi: 10.1038/s41586-023-05778-2. Epub 2023 Mar 8.

DOI:10.1038/s41586-023-05778-2
PMID:36890224
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10564584/
Abstract

Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development for solid tumours because most target antigens are shared with normal cells. Researchers have attempted to apply Boolean-logic gating to CAR T cells to prevent toxicity; however, a truly safe and effective logic-gated CAR has remained elusive. Here we describe an approach to CAR engineering in which we replace traditional CD3ζ domains with intracellular proximal T cell signalling molecules. We show that certain proximal signalling CARs, such as a ZAP-70 CAR, can activate T cells and eradicate tumours in vivo while bypassing upstream signalling proteins, including CD3ζ. The primary role of ZAP-70 is to phosphorylate LAT and SLP-76, which form a scaffold for signal propagation. We exploited the cooperative role of LAT and SLP-76 to engineer logic-gated intracellular network (LINK) CAR, a rapid and reversible Boolean-logic AND-gated CAR T cell platform that outperforms other systems in both efficacy and prevention of on-target, off-tumour toxicity. LINK CAR will expand the range of molecules that can be targeted with CAR T cells, and will enable these powerful therapeutic agents to be used for solid tumours and diverse diseases such as autoimmunity and fibrosis. In addition, this work shows that the internal signalling machinery of cells can be repurposed into surface receptors, which could open new avenues for cellular engineering.

摘要

尽管嵌合抗原受体 (CAR) T 细胞改变了 B 细胞恶性肿瘤的治疗格局,但由于大多数靶抗原与正常细胞共享,因此针对肿瘤的脱靶毒性风险阻碍了其在实体瘤中的发展。研究人员试图将布尔逻辑门控应用于 CAR T 细胞以防止毒性;然而,真正安全有效的逻辑门控 CAR 仍然难以捉摸。在这里,我们描述了一种 CAR 工程方法,我们用细胞内近端 T 细胞信号分子替代传统的 CD3ζ 结构域。我们表明,某些近端信号 CAR,如 ZAP-70 CAR,可以激活 T 细胞并在体内消除肿瘤,同时绕过包括 CD3ζ 在内的上游信号蛋白。ZAP-70 的主要作用是磷酸化 LAT 和 SLP-76,它们形成信号传导的支架。我们利用 LAT 和 SLP-76 的协同作用来设计逻辑门控细胞内网络 (LINK) CAR,这是一种快速且可逆转的布尔逻辑 AND 门控 CAR T 细胞平台,在疗效和预防针对肿瘤的脱靶毒性方面优于其他系统。LINK CAR 将扩大可以用 CAR T 细胞靶向的分子范围,并使这些强大的治疗剂能够用于实体瘤和多种疾病,如自身免疫和纤维化。此外,这项工作表明细胞的内部信号机制可以被重新用于表面受体,这可能为细胞工程开辟新的途径。

相似文献

1
Co-opting signalling molecules enables logic-gated control of CAR T cells.信号分子的协同作用使 CAR T 细胞的逻辑门控控制成为可能。
Nature. 2023 Mar;615(7952):507-516. doi: 10.1038/s41586-023-05778-2. Epub 2023 Mar 8.
2
Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function.设计用于组合抗原识别和CAR功能可逆控制的亲和CAR
Nat Commun. 2020 Aug 20;11(1):4166. doi: 10.1038/s41467-020-17970-3.
3
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.用于癌症治疗的多抗原靶向嵌合抗原受体 T 细胞。
J Hematol Oncol. 2019 Nov 29;12(1):128. doi: 10.1186/s13045-019-0813-7.
4
Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.逻辑门控方法扩展嵌合抗原受体 T 细胞技术的应用。
Biochem Soc Trans. 2018 Apr 17;46(2):391-401. doi: 10.1042/BST20170178. Epub 2018 Mar 14.
5
Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies.配备齐全的嵌合抗原受体(CARs)可解决肿瘤异质性问题,增强安全性,并提高细胞免疫疗法的功能。
Front Immunol. 2024 Jun 3;15:1407992. doi: 10.3389/fimmu.2024.1407992. eCollection 2024.
6
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.嵌合抗原受体信号的磷酸化蛋白质组学分析揭示了影响细胞功能的动力学和定量差异。
Sci Signal. 2018 Aug 21;11(544):eaat6753. doi: 10.1126/scisignal.aat6753.
7
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤和实体瘤:临床数据现状、当前局限性和展望。
Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003.
8
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.嵌合抗原受体 T 细胞免疫疗法治疗实体瘤的展望。
Front Immunol. 2018 May 22;9:1104. doi: 10.3389/fimmu.2018.01104. eCollection 2018.
9
Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy.结合型 CAR T 细胞:超越常规 CAR T 细胞的一步,为癌症免疫治疗带来新希望。
Cell Immunol. 2019 Nov;345:103963. doi: 10.1016/j.cellimm.2019.103963. Epub 2019 Aug 10.
10
Generation of CAR-T Cells for Cancer Immunotherapy.用于癌症免疫治疗的嵌合抗原受体T细胞的生成。
Methods Mol Biol. 2019;1884:349-360. doi: 10.1007/978-1-4939-8885-3_24.

引用本文的文献

1
Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression.肿瘤内外:胶质母细胞瘤诱导免疫抑制的机制
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv4-iv18. doi: 10.1093/noajnl/vdaf006. eCollection 2025 Sep.
2
Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer.用于治疗三阴性乳腺癌的TROP2特异性嵌合抗原受体T细胞的抗肿瘤活性和毒性的临床前评估。
J Immunother Cancer. 2025 Sep 3;13(9):e012442. doi: 10.1136/jitc-2025-012442.
3
CD4/CD8-p56 Induced T-Cell Receptor Signaling and Its Implications for Immunotherapy.

本文引用的文献

1
Enhanced safety and efficacy of protease-regulated CAR-T cell receptors.增强了受蛋白酶调控的嵌合抗原受体 T 细胞受体的安全性和有效性。
Cell. 2022 May 12;185(10):1745-1763.e22. doi: 10.1016/j.cell.2022.03.041. Epub 2022 Apr 27.
2
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.用于 H3K27M 突变型弥漫性中线脑胶质瘤的 GD2-CAR T 细胞疗法。
Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7.
3
Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity.
CD4/CD8-p56诱导的T细胞受体信号传导及其对免疫治疗的意义。
Biomolecules. 2025 Jul 29;15(8):1096. doi: 10.3390/biom15081096.
4
Optimised modular anti-FLAG CAR T cells for solid tumor therapy.用于实体瘤治疗的优化模块化抗FLAG嵌合抗原受体T细胞
Clin Transl Immunology. 2025 Aug 21;14(8):e70046. doi: 10.1002/cti2.70046. eCollection 2025.
5
SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.SCAN-ACT:通过单细胞转录组学发现过继性T细胞疗法的靶点
Genome Med. 2025 Aug 14;17(1):89. doi: 10.1186/s13073-025-01514-9.
6
Adoptive T-Cell Therapy in Sarcomas.肉瘤的过继性T细胞疗法
Curr Oncol Rep. 2025 Aug 14. doi: 10.1007/s11912-025-01706-x.
7
Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease.免疫突触:结构、分子机制及在疾病中的治疗意义
Signal Transduct Target Ther. 2025 Aug 11;10(1):254. doi: 10.1038/s41392-025-02332-6.
8
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.工程化过继性细胞免疫疗法中生物医学虚拟孪生体的设计规范。
NPJ Digit Med. 2025 Aug 1;8(1):493. doi: 10.1038/s41746-025-01809-6.
9
Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation.不一致的嵌合抗原受体T细胞信号传导:偏离生理性T细胞活化的影响
J Transl Med. 2025 Jul 25;23(1):834. doi: 10.1186/s12967-025-06857-w.
10
The Struggle Between Chimeric Antigen Receptor T-Cell Therapy and Neurological Complications in Acute Lymphoblastic Leukemia Treatment.嵌合抗原受体T细胞疗法与急性淋巴细胞白血病治疗中神经并发症之间的斗争
Curr Issues Mol Biol. 2025 May 21;47(5):381. doi: 10.3390/cimb47050381.
通过正常细胞的单细胞测序检测到的嵌合抗原受体疗法靶点的表达可能会导致肿瘤外毒性。
Cancer Cell. 2021 Dec 13;39(12):1558-1559. doi: 10.1016/j.ccell.2021.09.016. Epub 2021 Oct 21.
4
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.比较 TCR 和 CAR 信号转导,为具有优异抗原敏感性和体内功能的 CAR 设计提供信息。
Sci Signal. 2021 Aug 24;14(697):eabe2606. doi: 10.1126/scisignal.abe2606.
5
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛,一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法,用于治疗复发或难治性多发性骨髓瘤患者(CARTITUDE-1):一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
6
Integrated analysis of multimodal single-cell data.多模态单细胞数据的综合分析。
Cell. 2021 Jun 24;184(13):3573-3587.e29. doi: 10.1016/j.cell.2021.04.048. Epub 2021 May 31.
7
Recent advances and discoveries in the mechanisms and functions of CAR T cells.嵌合抗原受体 T 细胞的作用机制及功能的最新进展和发现。
Nat Rev Cancer. 2021 Mar;21(3):145-161. doi: 10.1038/s41568-020-00323-z. Epub 2021 Jan 22.
8
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?嵌合抗原受体 T 细胞疗法治疗实体瘤:光明的未来还是黑暗的现实?
Mol Ther. 2020 Nov 4;28(11):2320-2339. doi: 10.1016/j.ymthe.2020.09.015. Epub 2020 Sep 16.
9
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.单细胞分析鉴定出表达 CD19 的脑壁细胞,可能成为 CAR-T 免疫疗法的肿瘤外靶点。
Cell. 2020 Oct 1;183(1):126-142.e17. doi: 10.1016/j.cell.2020.08.022. Epub 2020 Sep 21.
10
Designed protein logic to target cells with precise combinations of surface antigens.设计蛋白质逻辑,以通过表面抗原的精确组合靶向细胞。
Science. 2020 Sep 25;369(6511):1637-1643. doi: 10.1126/science.aba6527. Epub 2020 Aug 20.